Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares 0 3 Month Treasury Bond ETF vs Viatris Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 5.7× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while iShares 0 3 Month Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 0 3 Month Treasury Bond ETF for 50 Days and Viatris Inc for 57 Days on average.
| SGOV | VTRS | |
|---|---|---|
Market Cap | $114.40B | $20.03B |
Volume | 18,879,081 | 14,109,977 |
Sector | Fixed Income | Health |
52-Week High | $100.72 | $18.27 |
52-Week Low | $100.28 | $9.74 |
Typical Hold Time | 50 Days | 57 Days |
Enterprise Value | — | $32.15B |
Dividend Yield | — | 2.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.515 with minimal daily movement, reflecting its stable nature. The technical picture is bearish according to moving averages, though oscillators are neutral. Recent corporate actions show consistent dividend payments. Market sentiment is influenced by broader bond market volatility and institutional positioning shifts.
The outlook for SGOV is tied to short-term Treasury yields and Federal Reserve policy. Opportunities include stability and income, but risks involve rising interest rates and institutional selling. Investors should weigh the ETF's defensive role against potential yield compression in a changing rate environment.
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
